Fundz
New|Fundz now works inside Claude2 min

Timing. Relevance. Relationships.

Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.

Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015

Verastem Oncology has priced a $250 million offering of common stock and pre-funded warrants. This offering includes approximately 30.9 million shares at $8.00 each.

PUBLIC · VSTMOct 14, 2026

Amount Raised

$250 Million

Round Type

Venture

NeedhamBiotechnologyHealthcareHealth CareTherapeuticsBiopharma

Description

Verastem Oncology, a biopharmaceutical company, announced the pricing of its underwritten offering totaling $250 million. This includes 30,937,500 shares of common stock priced at $8.00 per share. Additionally, pre-funded warrants for purchasing shares were also offered. The capital raised will support their development efforts in cancer treatments.

Company Information

Company

Verastem Oncology

Location

117 Kendrick Street, Suite 500

Needham, Massachusetts, United States

About

Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition.

Fundz sees it the moment Verastem Oncology raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts12 people are listed at Verastem Oncology. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Verastem Oncology's next move

See what Strategic adds

Verastem Oncology raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.